0
Signin
countryflagUS

18889881171

AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

PreveCeutical Medical Inc

Healthcare US PRVCF

0.0164USD
0.0014(9.33%)

Last update at 2024-05-16T15:41:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.010.03
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax -1.74705M -3.80727M -3.58677M -11.92448M -7.32888M
Minority interest - - - - -
Net income -1.72657M -3.80112M -3.57890M -11.88413M -7.23189M
Selling general administrative 0.83M 1.88M 1.67M 4.54M 3.97M
Selling and marketing expenses - - - - -
Gross profit - 0.00000M 0.00225M 0.01M 0.01M
Reconciled depreciation 0.00509M 0.08M 0.17M 0.04M 0.02M
Ebit -0.83492M -2.09329M -3.43582M -6.92295M -4.44209M
Ebitda -1.27506M -3.09206M -2.83355M -11.33911M -7.21067M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -0.89785M -2.16323M -3.50734M -6.92718M -4.49334M
Other operating expenses - - - 0.06M 0.06M
Interest expense 0.47M 0.64M 0.58M 0.55M 0.00000M
Tax provision -0.02048M -0.00615M -0.00788M -0.04035M -0.09700M
Interest income - - - - -
Net interest income -0.46690M -0.64004M -0.57869M -0.54907M -0.09891M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.02048M -0.00615M -0.00788M -0.04035M -0.09700M
Total revenue 0.00000M 0.00000M 0.00303M 0.02M 0.02M
Total operating expenses 0.90M 2.16M 3.51M 6.94M 4.52M
Cost of revenue - 0.00000M 0.00078M 0.00472M 0.00793M
Total other income expense net -0.38230M -1.00399M 0.50M -4.44823M -2.73664M
Discontinued operations - - - - -
Net income from continuing ops -1.72657M -3.80112M -3.57890M -11.88413M -7.23189M
Net income applicable to common shares -1.72657M -3.80112M -3.57890M -11.88413M -7.23189M
Preferred stock and other adjustments - - - - -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets 0.16M 0.30M 0.86M 1.90M 2.60M
Intangible assets 0.08M 0.02M 0.03M 0.03M 0.03M
Earning assets - - - - -
Other current assets - 0.00066M 0.12M 1.07M 0.97M
Total liab 4.27M 3.91M 5.34M 4.19M 2.94M
Total stockholder equity -4.10402M -3.60395M -4.48678M -2.28517M -0.34434M
Deferred long term liab - - - - -
Other current liab - - - - 0.02M
Common stock 18.56M 17.57M 13.18M 12.90M 6.00M
Capital stock 18.56M 17.57M 13.18M 12.90M -
Retained earnings -28.52649M -26.91870M -23.68456M -21.63266M -10.48211M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00575M 0.09M 0.41M 1.05M
Cash 0.02M 0.16M 0.03M 0.06M 0.10M
Cash and equivalents - - - - -
Total current liabilities 2.59M 2.03M 1.83M 1.14M 0.30M
Current deferred revenue - - - - -
Net debt 2.91M 2.86M 4.36M 3.59M 2.62M
Short term debt - - - 0.61M 0.09M
Short long term debt 1.25M 1.14M 1.09M 0.61M 0.09M
Short long term debt total - - - - -
Other stockholder equity 5.86M 5.75M 6.02M 6.44M 4.14M
Property plant equipment 0.00223M 0.00904M 0.45M 0.12M 0.15M
Total current assets 0.08M 0.26M 0.29M 1.34M 1.37M
Long term investments - - - - -
Net tangible assets -4.18031M -3.62861M -4.51233M -2.31263M -0.37204M
Short term investments - - - - -
Net receivables 0.05M 0.09M 0.10M 0.08M 0.08M
Long term debt 1.68M 1.88M 3.30M 3.04M 2.64M
Inventory - - - 0.00000M 0.06M
Accounts payable 0.38M 0.15M 0.45M 0.48M 0.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.57M 0.56M 1.23M
Deferred long term asset charges - - - - -
Non current assets total 0.08M 0.04M 0.57M 0.56M 1.23M
Capital lease obligations - 0.00000M 0.36M - -
Long term debt total - - - - -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments -0.05270M -0.00265M -0.00133M -0.01058M 1.53M
Change to liabilities 0.55M 0.49M 0.07M 0.34M 0.00985M
Total cashflows from investing activities -0.05270M -0.00265M -0.00133M -0.01058M 1.53M
Net borrowings 0.14M 0.18M 0.59M 0.99M 2.90M
Total cash from financing activities 0.14M 0.18M 0.87M 7.55M 2.92M
Change to operating activities 0.00998M 0.21M 1.35M -2.21837M -1.10991M
Net income -1.72657M -3.80112M -3.57890M -11.88413M -7.23189M
Change in cash -0.14038M 0.13M -0.03585M -0.04015M 0.15M
Begin period cash flow 0.16M 0.03M 0.06M 0.10M -0.04704M
End period cash flow 0.02M 0.16M 0.03M 0.06M 0.10M
Total cash from operating activities -0.42639M 0.06M -0.99394M -7.57303M -4.29904M
Issuance of capital stock 0.00000M 0.00000M 0.28M 6.26M -
Depreciation 0.00509M 0.08M 0.17M 0.04M 0.02M
Other cashflows from investing activities - - - - 1.35M
Dividends paid - - - - -
Change to inventory - - 0.00000M 0.00420M 0.00262M
Change to account receivables 0.04M 0.00609M -0.02035M -0.00020M -0.04300M
Sale purchase of stock - - - - 0.02M
Other cashflows from financing activities - - -0.02569M -0.02569M -0.02569M
Change to netincome 0.70M 3.09M 1.00M 3.38M 1.47M
Capital expenditures 0.06M 0.00265M 0.00133M 0.00767M 0.17M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.59M 0.70M 1.41M -1.87539M -1.14045M
Stock based compensation 0.09M 1.17M 0.43M - -
Other non cash items 0.46M 0.63M 0.58M 0.67M 2.76M
Free cash flow -0.48159M 0.06M -0.99527M -7.58361M -4.49200M

Fundamentals

  • Previous Close 0.01
  • Market Cap10.71M
  • Volume10000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.81632M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00225M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRVCF
PreveCeutical Medical Inc		 0.0014 9.33% 0.02 - - 3901.83 - 2961.84 -7.9819
NVO
Novo Nordisk A/S		 -1.63 1.21% 133.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.57 0.43% 132.69 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.20 0.27% 438.69 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.03 1.09% 96.00 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.

PreveCeutical Medical Inc

885 Cambie Street, Vancouver, BC, Canada, V6B 0R6

Key Executives

Name Title Year Born
Mr. Stephen Van Deventer Chairman & CEO 1969
Dr. Makarand Jawadekar Ph.D. Chief Science Officer, Pres & Director 1951
Ms. Shabira Rajan CPA, CGA CFO & Controller 1956
Dr. Harendra Parekh Ph.D., BSc., Hons I, MRPharmS Chief Research Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).